Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid beta Antibody in Patients With Alzheimer's Disease.

Trial Profile

Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid beta Antibody in Patients With Alzheimer's Disease.

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 23 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Solanezumab (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Registrational
  • Acronyms EXPEDITION-EXT
  • Sponsors Eli Lilly and Company

Most Recent Events

  • 18 Dec 2021 This trial has been completed in Italy, according to European Clinical Trials Database record. (17 Feb-2017)
  • 29 Mar 2017 This trial has been completed in Spain (End date:2017-02-17) as per European Clinical Trials Database record.
  • 07 Mar 2017 Status changed from active, no longer recruiting to discontinued.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top